EJU1 Stock Chart & Stats
€1.89
€0.00(0.00%)
At close: 4:00 PM EDT
€1.89
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.89 - €1.89
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.29M
Enterprise Value-€1.07
Total Cash (Recent Filing)€5.03M
Total Debt (Recent Filing)€336.72K
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Aug 12, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.89
Shares Outstanding2,633,560
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.74Price Target Upside-8.07% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressIndependent DSMB clearance for Cohort 2 and initiation of Cohort 3 demonstrate consistent clinical execution and reduced safety risk. Advancing dosing cohorts and collecting biomarker/T‑cell data materially de‑risks development, supporting future larger trials, regulatory engagement, and credible partner discussions over the medium term.
Expense Discipline & Improved LossesA 21.9% reduction in consolidated operating expenses and a ~46% improvement in net loss indicate durable management focus on cost control. Lower structural burn per period extends runway per financing dollar, improves capital efficiency for clinical programs, and makes future financing needs smaller or more targeted if sustained.
Device Compatibility With Simplified PumpSuccessful compatibility with a simplified blood pump enables potential treatments outside dialysis units, supports less invasive vascular access, and reduces site setup complexity. This structural interoperability enhances the Hemopurifier’s scalability and adoption potential across more sites and indications if later commercialized.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flows mean the company cannot internally fund development. Chronic cash burn forces reliance on external capital, increasing execution risk, potentially slowing or pausing trials if financing stalls, and limiting investments in manufacturing, regulatory work, or commercial readiness over the medium term.
Limited Liquidity Vs. BurnYear‑end cash plus recent ATM proceeds appear insufficient relative to annual operating losses, creating near‑term runway pressure. This funding gap makes program pacing and enrollment timelines contingent on securing additional capital, increasing the chance of delays in pivotal studies or narrowing strategic options for partnerships.
Dependence On Equity FinancingRepeated reliance on equity raises, ATM sales and recent financings — plus capital structure actions like a reverse split — signal dependence on dilutive funding. This constrains long‑term planning, risks shareholder dilution, and may limit ability to attract non‑dilutive partners or favorable deal terms absent clearer clinical de‑risking.
Aethlon Medical News
EJU1 FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Aethlon Medical Inc lowest stock price was €1.89 and its highest was €1.89 in the past 12 months.
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is €1.29M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Jun 10, 2026. The company reported €3.537 earnings per share for the quarter, beating the consensus estimate of -€1.877 by €5.414.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Overvalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -0.68.
How many shares outstanding does Aethlon Medical Inc have?
Aethlon Medical Inc has 2,633,560 shares outstanding.
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of €3.537 in its last earnings report, beating expectations of -€1.877. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in DE:EJU1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
EJU1 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated multiple operational and clinical progress points — completion of Cohort 2 with DSMB clearance, initiation of Cohort 3 with a successful first treatment, expansion of preclinical EV research into rheumatoid arthritis and chronic kidney disease, successful compatibility testing with a simplified blood pump, disciplined cost reductions (operating expenses down 21.9%), and an improved net loss (~46% reduction). However, material challenges remain: cash at fiscal year‑end was modest (~$5.0M) despite a subsequent ~$1.85M ATM raise, the company remains unprofitable (net loss $7.2M), the current oncology study is small and not powered for efficacy, and there is no near‑term commercial revenue or explicit commercialization timeline. Overall, operational and clinical execution trends are positive but balanced by funding and development‑stage risks.View all DE:EJU1 earnings summariesEJU1 Stock 12 Month Forecast
Average Price Target
€1.74
▼(-8.07% Downside)